|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||22.2039 - 22.2039|
|52 Week Range||18.2500 - 22.3900|
|PE Ratio (TTM)||261.22|
|Expense Ratio (net)||0.30%|
In 1H17, Novartis’s (NVS) Lucentis reported revenues of around $922 million, which is a ~1% decline on a year-over-year (or YoY) basis.
In 1H17, Teva Pharmaceutical's (TEVA) respiratory franchise reported revenues of ~$626 million, or ~8% lower YoY (year-over-year).
At constant exchange rates, AstraZeneca reported an 8% decline in its product sales of ~$4.9 billion during 2Q17.